August 2012
-
Respira Therapeutics has issued a press release to introduce its drug engine technology (DET) dry powder inhaler, which the company says “can be deployed and optimized in short test cycles with a wide range of… Read more . . .
-
University of Melbourne spin-off Otifex has reportedly raised $1.1 million for the development of a nasal spray to treat otitis media with effusion (OTE), in which viscous fluid builds up in the middle ear, potentially… Read more . . .
-
The US FDA has granted orphan drug designation to Aradigm Corporation’s dual release ciprofloxacin for inhalation (DRCFI) for the treatment of bronchiectasis. The company’s liposomal ciprofloxacin for inhalation (CFI) already has orphan drug designation from… Read more . . .
-
Reuters is reporting that the Swedish Medical Products Agency has approved a fluticasone/salmeterol DPI manufactured by Greek pharmaceutical company Elpen. The approval apparently took place in May 2011 but was not announced. The company has… Read more . . .
-
DDL 22 committee member Mark Hammond has organized a new group on LinkedIn called “DDL Conference” in order to “provide updates to the programme and this years conference as they become available and also give… Read more . . .
-
A Phase 1 clinical trial of an inhaled dry powder formulation of atropine for the treatment of nerve agent poisoning has been completed successfully, according to MicroDose Therapeutx. MicroDose subsidiary MicroDose Defense Products is developing… Read more . . .
-
Copley Scientific will introduce its new breath simulator at the upcoming ISAM 2011 congress in Rotterdam, The Netherlands. New pharmacopoeial testing specifications for nebulizers take effect in August 2011, and the new breath simulator allows… Read more . . .
-
The US FDA has accepted the filing of the new drug application for its ciclesonide nasal aerosol, according to Nycomed and Sunovion. The product is an HFA formulation of ciclesonide delivered by a metered dose… Read more . . .
-
Canadian biotech company Asmacure has announced that Martin Driscoll will replace Luc Vachon as Chief Executive Officer. Vachon is leaving the company “to pursue other business ventures.” Asmacure is developing an inhaled nictonic receptor agonist,… Read more . . .
-
GSK and Theravance have announced results for two Phase 3 studies of its ICS/LABA combo DPI Relovair for the treatment of COPD. The product combines fluticasone furoate and vilanterol. The companies said that the studies… Read more . . .
Featured event:
5th Annual Inhaled & Nasal Biologics | DNA Forum
5th Annual Inhaled & Nasal Biologics | DNA Forum
24th-25th September 2026, Cambridge, UK
Join us for a ground-breaking and insightful forum: Two days of cutting-edge talks and networking opportunities in this complex area of drug and vaccine development.
With renowned industry leaders who will share their insights and real-world case studies, our speakers will explore innovative formulation and delivery technologies and the rationale behind overcoming development challenges. Don’t miss out on this opportunity to learn more about key topics shaping the future of inhaled therapeutics.
Get online to see speakers announced so far. Registration is live – save your seat now!
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
No events are found.